Skip to main content

Advertisement

Table 2 Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) of the DNA methylation biomarkers (RARB, RASSF1, and GSTP1) and PSA for predicting upstaging, upgrading, and risk group increase

From: Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging

Parameter Upstaging Upgrading Risk change
Sensitivity, % Specificity, % PPV, % NPV, % Sensitivity, % Specificity, % PPV, % NPV, % Sensitivity, % Specificity, % PPV, % NPV, %
Voided urine (N = 188)
 PSA 86.7 27.9 23.4 89.1 82.6 27.0 29.7 80.6 85.0 27.4 26.9 85.3
RARB, RASSF1, GSTP1 52.3 72.5 32.6 85.6 50.7 67.5 36.9 78.6 45.8 71.3 33.4 80.7
RARB, RASSF1, GSTP1+PSA 56.8 65.2 29.4 85.6 47.8 74.6 41.2 79.3 89.8 27.0 27.9 89.4
RASSF1, GSTP1 50.0 73.9 32.8 85.3 50.7 69.3 35.7 78.1 45.8 71.3 33.4 80.7
RASSF1, GSTP1+PSA 54.5 66.7 27.7 84.6 40.3 81.6 45.0 78.5 89.8 27.0 27.9 89.4
Catheterized urine (N = 326)
 PSA 73.1 51.4 27.7 88.2 66.1 64.8 41.2 87.3 58.2 62.6 32.8 82.7
RARB, RASSF1, GSTP1 68.7 43.7 23.7 84.6 63.8 54.8 34.5 80.2 30.2 82.4 35.0 79.0
RARB, RASSF1, GSTP1+PSA 60.9 63.3 29.7 86.4 56,9 79,2 50.5 83.1 56.6 62.1 31.2 81.4
RASSF1, GSTP1 67.2 53.9 27.1 86.6 84.5 3.6 24.7 38.4 35.8 75.8 31.7 79.0
RASSF1, GSTP1+PSA 65.6 64.9 27.5 86.5 55.2 80.5 51.4 82.8 58.5 61.2 32.2 82.4